RNA binding motif protein 48Genealiases: C7orf64 · HSPC304
Q-omics provides the consensus-scored RBM48 profile across patient tissues and cancer cell-line models. RBM48 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, RBM48 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, RBM48 RNA expression shows 20,665 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, HNSC, and ACC as cancer lineages where RBM48 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBM48 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBM48 survival associations across molecular data types. RBM48 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBM48 RNA expression–survival associations across cancer types. High RBM48 expression shows unfavorable associations in KICH, LIHC, LGG and UVM, but favorable associations in KIRC and UCS. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for RBM48 RNA expression.
This table summarizes RBM48 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for RBM48. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBM48 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, LIHC, CHOL and COAD. The HNSC box plot shows higher RBM48 RNA expression in tumor versus normal tissue (log2 FC = +0.645, t-test p < 0.001).
This table shows molecular features associated with RBM48 in patient tissues and cancer cell lines. In patient samples, RBM48 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RBM48 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
